Advancing Early Cardiovascular Drug Discovery
Webinar Date: June 13, 2017
Innovation continues to be a primary driver of value in pharmaceutical research. However, simultaneously, research budgets are coming under ever increasing pressure. As a consequence, pharma is moving toward a so-called “open research” model wherein recurrent fixed costs are redirected toward a more flexible and dynamic external spend and offers the potential to tap into innovation outside their walls. In this webinar, case studies will be presented highlighting the value of such collaborations, while focusing on discovery campaigns that employ highly relevant functional assays. Using an integrated approach that fuses together the disciplines of in silico drug design, medicinal chemistry, and discovery biology the presenters will demonstrate their unique approach and discuss how key goals were met during the early discovery process, as well as which factors contributed to current successes. Making medicines these days cannot be done in isolation. And the story presented in this webinar shows an excellent example of a partnership in action for developing new treatments to support unmet pharmaceutical needs.
Webinar attendees will learn about:
- Recent advances in the early drug discovery process
- The importance of tight integration of disciplines in addressing challenging targets
- How collaboration in early discovery can create high-quality advanced leads
Discussions lead by:
Robert S. McDowell, M.D., Ph.D.
Senior Vice President, Drug Discovery, MyoKardia
Kenneth F. Wertman, Ph.D.
Senior Vice President, Icagen